Hadassah University Medical Center Conducts Clinical Trial for Vaccine Against Cancer Cells
The Hadassah University Medical Center is participating in a clinical trial of a vaccine that 'trains' the immune system to seek and destroy malignant cells that have invaded the body.
The vaccine, entitled ImMucin and developed in Israel by Vaxil BioTherapeutics, does not prevent cancer from invading; it does, however, activate and enhance the body's natural immune system so it will destroy cancer cells that, for example, linger following cancer surgery. The vaccine is currently being tested against a blood cancer called multiple myeloma, a cancer of the blood. The drug is based on a drug platform called VaxHit, which can be tailored to treat not only 90 percent of cancers, but also diseases such as tuberculosis, according to Vaxil's Chief Executive Officer, Julian Levy.
Hadasit, Hadassah’s Technology Transfer Arm, Reviews
When the Hadassah University Medical Center’s physicians suggest a
solution to a medical problem which can lead to the development of a new
medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its
feasibility and supports the promotion of those viable ideas with innovation
potential. Although 2012 has been “a year full of challenges for the life
science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer,
Hadasit still signed 125 agreements for clinical trials, all to be done at
Hadassah. In addition, Hadasit signed 15 agreements for cooperation and
commercialization of technologies that were developed at Hadassah. Click here
to read the latest Newsletter from Hadasit >>